A Comparative Study of Efficacy and Safety of Eberconazole Versus Terbinafine in Patients of Tinea versicolor

Authors

  • Iqbal Shah Imamzai Lecturer, Dermatology Department, Medical Faculty, Nangarhar University, Jalalabad, Afghanistan
  • Raihanullah Zwaak Lecturer, Dermatology Department, Medical Faculty, Nangarhar University, Jalalabad, Afghanistan

DOI:

https://doi.org/10.53555/bp.v6i3.1244

Keywords:

Tinea vesrsicolor, Eberconazole, Terbinafine, Clinical and Mycological response.

Abstract

Tinea versicolor is a common fungal disease that is finding in the summer months and usually affected trunk and proximal extremities. The aim of present study to compare the topical usage of eberconazole versus terbinafine in Tinea versicolor patients. This was an open-label, randomized, comparative clinical trial conducted on sixty patients in Nangarhar University Teaching hospital from May 2019 to October 2019. Informed consent was obtained from all patients enrolled for the study. An adequate number of patients were screened and selected as per the inclusion and exclusion criteria for the study. No statistically significant difference in improvement regarding physician assessment 4-point scale was seen in comparing both groups at week 2. However, statistically significant improvement was seen with eberconazole as compared to terbinafine in pruritus score at the end of week 1. Clinical cure at the end of week 1 and 2 was better with eberconazole than terbinafine. Mycological cure at the end of week 2 was also better with eberconazole than terbinafine.  On comparing both treatment groups, the better response was observed with eberconazole as patients had earlier clinical and mycological cure and no patient relapsed in the follow-up.

Downloads

Download data is not yet available.

References

Goslen JB, Kobayashi GS. Mycologic infections. In: Fitzpatrick TB, Eisen AZ, Wolf K, Freedberg IM, Austen KF, editors. Dermatology in General Medicine. 3rd ed. New York: McGraw Hill Book Company; 1987. pp. 2197–200.

Roberts SO. Pityriasis versicolor: A clinical and mycological investigation. Br J Dermatol. 1969; 81:315–26.

Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: Clinical experience with Lamisil cream and Lamisil DermGel. Dermatology. 1997; 194(Suppl 1):19–21.

High W, Fitzpatrick J. Topical antifungal agents. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffel D, editors. Fitzpatrick's Dermatology in General Medicin.7th ed. New York: McGraw Hill; 2007. pp. 2116–21.

Moodahadu-Bangera LS, Martis J, Mittal R, Krishnankutty B, Kumar N, Bellary S, et al. Eberconazole – Pharmacological and clinical review. Indian J Dermatol Venereol Leprol. 2012; 78:217–22.

Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F, et al. Eberconazole cream: Topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol. 2005; 27:227–34.

Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014; 5:128–31.

Chopra V, Jain VK. Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor. Indian J Dermatol Venereol Leprol. 2000; 66:299–300.

Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR, et al. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: Multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int J Dermatol. 2006; 45:600–4.

del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E, et al. A double-blind randomized comparative trial: Eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections. Mycoses. 2001; 44:173–80.

Downloads

Published

2020-03-31

How to Cite

Imamzai, I. S., & Zwaak, R. (2020). A Comparative Study of Efficacy and Safety of Eberconazole Versus Terbinafine in Patients of Tinea versicolor. International Journal For Research In Biology & Pharmacy, 6(3), 01–08. https://doi.org/10.53555/bp.v6i3.1244

Issue

Vol. 6 No. 3 (2020): International Journal For Research In Biology & Pharmacy (ISSN: 2208-2093)

Section

Articles

License

Copyright (c) 2020 International Journal For Research In Biology & Pharmacy (ISSN: 2208-2093)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.

By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in